Posters & Presentations
PHenomenal Hope
December 2024
A retrospective study investigating the real-world use of monotherapy in pulmonary arterial hypertension (PAH) In the US
DownloadPHenomenal Hope
December 2024
Best practices for managing cough in PAH patients receiving inhaled therapies
DownloadPVRI LATAM
November 2024
Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells
DownloadPVRI LATAM
November 2024
Trial in progress: Prosera, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension
DownloadPVRI LATAM
November 2024
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension: Results of the Torrey phase 2 imaging substudy
DownloadPVRI LATAM
November 2024
Interim results from the phase 1B and phase 2 Torrey open-label extension study of seralutinib in pulmonary arterial hypertension
DownloadPVRI LATAM
November 2024
Sustained benefit with seralutinib treatment: A post-hoc analysis of the Torrey open-label extension
DownloadPVRI LATAM
November 2024
Sustained effect of seralutinib on circulating biomarkers in the Torrey phase 2 open-label extension study
DownloadCHEST
October 2024
Current treatment patterns in pulmonary arterial hypertension (PAH): Real-world data from a contemporary U.S. Physician survey
DownloadCHEST
October 2024
Seralutinib exhibits anti-fibrotic effects in human models of pulmonary fibrosis: an emerging option for group 1 and 3 pulmonary hypertension?
DownloadERS
September 2024
Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension
DownloadERS
September 2024
Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study
DownloadERS
September 2024
Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells
DownloadPHA
August 2024
PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
DownloadPHA
August 2024
A retrospective study investigating the real-world use of monotherapy in pulmonary arterial hypertension in the US
DownloadPHA
August 2024
Interim Results from the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib in Pulmonary Arterial Hypertension
DownloadPHA
August 2024
The Clinical Development of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension
DownloadWSPH
June 2024
Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
DownloadWSPH
June 2024
Effects of inhaled seralutinib on right ventricular-pulmonary arterial coupling and right heart function in pulmonary arterial hypertension
DownloadWSPH
June 2024
Interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension
DownloadWSPH
June 2024
TORREY phase 2 study of seralutinib in pulmonary arterial hypertension: Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
DownloadWSPH
June 2024
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension: Results of the TORREY Phase 2 imaging substudy
DownloadATS
May 2024
Cardiac effort is less variable than six-minute walk distance, correlates with hemodynamics and is consistent with REVEAL 2.0 risk score in a sub-study of the TORREY phase 2 PAH trial
DownloadATS
May 2024
TORREY phase 2 study of seralutinib in pulmonary arterial hypertension (PAH): Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
DownloadATS
May 2024
Interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension (PAH)
DownloadPVRI
January 2024
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging sub-study
DownloadPVRI
January 2024
Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
DownloadPVRI
January 2024
Effects of inhaled Seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
DownloadPHenomenal Hope
December 2023
Understanding Drivers and Barriers to Participation in Clinical Trials for Patients with Pulmonary Arterial Hypertension (PAH)
DownloadPHPN
September 2023
Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy
DownloadPHPN
September 2023
Effects of Inhaled Seralutinib on Right Ventricular-Pulmonary Arterial (RV-PA) Coupling and Right Heart Function in Pulmonary Arterial Hypertension (PAH)
DownloadPHPN
September 2023
Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 TORREY Trial
DownloadERS
September 2023
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging substudy
DownloadESC
August 2023
Effects of Inhaled Seralutinib on Right Ventricular Pulmonary Arterial Coupling and Right Heart Function in Pulmonary Arterial Hypertension
DownloadATS
May 2023
Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results from the Phase 2 TORREY Study (Plain Language Summary)
DownloadATS
May 2023
Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
DownloadATS
May 2023
Seralutinib Treatment in Adult Subjects With Pulmonary Arterial Hypertension: Results From the TORREY Study (Presentation)
DownloadCHEST
October 2022
Real-world referral patterns of PAH patients to pha-accredited comprehensive care centers in the state of Texas 2019-2020
DownloadERS
September 2022
Quantitative Immunohistochemistry of PDGFRα, PDGFRβ, c-KIT and CSF1R in Human PAH Lung Samples
DownloadPVRI
June 2022
Phase 1 Drug-Drug Interaction Studies of Inhaled Seralutinib in Healthy Subjects
DownloadPHA
June 2022
Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
DownloadPHA
June 2022
A phase 1, open-label study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects
DownloadPHA
June 2022
Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study
DownloadPHA
June 2022
Understanding Drivers and Barriers to Participation in Clinical Trials for Patients With Pulmonary Arterial Hypertension (PAH)
DownloadCHEST
October 2021
Functional class and physician-perceived severity are similar in treated and untreated patients with pulmonary arterial hypertension: A real-world survey
DownloadPHPN
October 2021
A Phase 1b, Multi-center, Randomized, Placebo-controlled Trial of Inhaled Seralutinib in Subjects with WHO Group 1 Pulmonary Arterial Hypertension
DownloadERS
September 2021
Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study
DownloadPHPN
September 2021
Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
DownloadATS
May 2021
A Phase 1B, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
DownloadISHLT
April 2021
Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
DownloadERS
September 2020
Pharmacologic Characterization of GB002, a Novel Inhaled PDGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH)
DownloadATS
August 2020
Phase 1a Randomized Double-Blind Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Studies of Orally Inhaled GB002 in Healthy Adult Subjects
DownloadPVRI DDS
June 2020
Clinical Development of Inhaled GB002 for the Treatment of Pulmonary Arterial Hypertension
DownloadAHA
November 2019
In Vivo Efficacy of a novel, inhaled PDGFRα/β inhibitor, GB002, in the Rat Monocrotaline and Pneumonectomy Model of Pulmonary Arterial Hypertension
DownloadAHA
November 2019
GB002, a Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in the SU5416 Hypoxia Rat Model of PAH
DownloadJournal Articles
The Lancet
July 2024
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
Read MoreInternational Journal of Molecular Sciences
August 2023
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension
Read MoreEuropean Respiratory Journal
June 2022
Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension
Read MorePulmonary Circulation
October 2021
TORREY, a Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Read More